Trailing-twelve-month (TTM) revenue is $1.43 Billion with a year-over-year growth of (3.72%). Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q1 FY2026Period ended 2025-09-30 | $365,603,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-06 |
| Q2 FY2026Period ended 2025-12-31 | $341,280,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-05 |
| Q3 FY2026Period ended 2026-03-31 | $352,922,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-06 |
| Q4 FY2026Period ended 2026-06-30 | $371,573,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-19 |
| TTM revenue | $1,431,378,000 |
Current P/S: $693,811,486 market capitalization ÷ $1,431,378,000 TTM revenue = 0.48x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T17:49:54.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q4 FY2026 (2026-06-30): $371.57M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T17:52:07.305Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2026-06-30 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2026-06-30 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20212021-06-30 · USD | FY20222022-06-30 · USD | FY20232023-06-30 · USD | FY20242024-06-30 · USD | FY20252025-06-30 · USD | FY20262026-06-30 · USD |
|---|---|---|---|---|---|---|
| Automotive | $552M | $582M | $820M | $826M | $738M | $657M |
| Industrial | $294M | $308M | $475M | $462M |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20212021-06-30 · USD | FY20222022-06-30 · USD | FY20232023-06-30 · USD | FY20242024-06-30 · USD | FY20252025-06-30 · USD | FY20262026-06-30 · USD |
|---|---|---|---|---|---|---|
| CHINA | $180M | $205M | $254M | $248M | $259M | $237M |
| MEXICO | $265M | $317M | $503M | $519M |
$1.43B
$1.43 Billion
(3.72%)
vs. $1.49B a year ago (TTM)
+2.07%
5 Year compound annual growth rate
1 Year
(3.72%)
3 Year
(7.75%)
5 Year
+2.07%
10 Year
+5.45%
15 Year
+4.67%
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2026 | $1.43B | ($55.33M) | (3.72%) |
| 2025 | $1.49B | ($227.78M) | (13.29%) |
| 2024 | $1.71B | ($108.92M) | (5.97%) |
| 2023 | $1.82B | +$473.89M | +35.12% |
| 2022 | $1.35B | +$57.73M | +4.47% |
| 2021 |
TTM Growth
(3.72%)
3-Year CAGR
(7.75%)
5-Year CAGR
+2.07%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T17:52:07.305Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $353M |
| $362M |
| Medical | $385M | $392M | $494M | $426M | $396M | $413M |
|---|
| Other | $14M | $17M | $35M | N/A | N/A | N/A |
|---|
| Public Safety | $48M | $50M | N/A | N/A | N/A | N/A |
|---|
| $360M |
| Other Foreign | $117M | $104M | $136M | $109M | $66M | $94M |
|---|
| POLAND | $268M | $234M | $302M | $261M | $242M | $289M |
|---|
| THAILAND | $100M | $152M | $233M | $171M | $132M | $159M |
|---|
| UNITED STATES | $360M | $338M | $395M | $405M | $342M | $294M |
|---|
| $1.29B |
| +$91.26M |
| +7.60% |
| 2020 | $1.20B | +$18.71M | +1.58% |
| 2019 | $1.18B | +$109.78M | +10.24% |
| 2018 | $1.07B | +$141.15M | +15.16% |
| 2017 | $930.91M | +$88.85M | +10.55% |
